Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients
Saved in:
| Published in | Blood Vol. 127; no. 3; pp. 360 - 362 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
21.01.2016
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Author | Jedrzejczak, Wieslaw Wiktor Holowiecki, Jerzy Grosicki, Sebastian Giebel, Sebastian Borg, Katarzyna Piatkowska-Jakubas, Beata Gadomska, Grazyna Kielbinski, Marek Libura, Jolanta Karabin, Karolina Paluszewska, Monika Czekalska, Sylwia Kuliczkowski, Kazimierz Solarska, Iwona Jazwiec, Bozena Kata, Dariusz Florek, Izabella Calbecka, Malgorzata Haus, Olga Zawada, Magdalena Jakobczyk, Malgorzata Ejduk, Anna Matiakowska, Karolina Wierzbowska, Agnieszka Skotnicki, Aleksander Kyrcz-Krzemien, Slawomira Warzocha, Krzysztof Gajkowska-Kulik, Justyna Pawelczyk, Marta Libura, Marta |
|---|---|
| Author_xml | – sequence: 1 givenname: Marta orcidid: 0000-0002-5344-345X surname: Libura fullname: Libura, Marta email: marta.libura@gmail.com organization: Medical University of Warsaw, Warsaw, Poland – sequence: 2 givenname: Sebastian surname: Giebel fullname: Giebel, Sebastian organization: Maria Sklodowska-Curie Institute of Oncology, Gliwice, Poland – sequence: 3 givenname: Beata surname: Piatkowska-Jakubas fullname: Piatkowska-Jakubas, Beata organization: Faculty of Medicine, Jagiellonian University, Cracow, Poland – sequence: 4 givenname: Marta surname: Pawelczyk fullname: Pawelczyk, Marta organization: Medical University of Warsaw, Warsaw, Poland – sequence: 5 givenname: Izabella surname: Florek fullname: Florek, Izabella organization: Faculty of Medicine, Jagiellonian University, Cracow, Poland – sequence: 6 givenname: Karolina surname: Matiakowska fullname: Matiakowska, Karolina organization: Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Bydgoszcz, Poland – sequence: 7 givenname: Bozena surname: Jazwiec fullname: Jazwiec, Bozena organization: Medical University of Wroclaw, Wroclaw, Poland – sequence: 8 givenname: Katarzyna surname: Borg fullname: Borg, Katarzyna organization: Institute of Hematology and Transfusion Medicine, Warsaw, Poland – sequence: 9 givenname: Iwona surname: Solarska fullname: Solarska, Iwona organization: Institute of Hematology and Transfusion Medicine, Warsaw, Poland – sequence: 10 givenname: Magdalena surname: Zawada fullname: Zawada, Magdalena organization: Faculty of Medicine, Jagiellonian University, Cracow, Poland – sequence: 11 givenname: Sylwia surname: Czekalska fullname: Czekalska, Sylwia organization: Faculty of Medicine, Jagiellonian University, Cracow, Poland – sequence: 12 givenname: Jolanta surname: Libura fullname: Libura, Jolanta organization: Medical University of Warsaw, Warsaw, Poland – sequence: 13 givenname: Malgorzata surname: Jakobczyk fullname: Jakobczyk, Malgorzata organization: Faculty of Medicine, Jagiellonian University, Cracow, Poland – sequence: 14 givenname: Karolina surname: Karabin fullname: Karabin, Karolina organization: Medical University of Warsaw, Warsaw, Poland – sequence: 15 givenname: Monika surname: Paluszewska fullname: Paluszewska, Monika organization: Medical University of Warsaw, Warsaw, Poland – sequence: 16 givenname: Malgorzata surname: Calbecka fullname: Calbecka, Malgorzata organization: Nicolaus Copernicus Municipal Specialist Hospital, Torun, Poland – sequence: 17 givenname: Justyna surname: Gajkowska-Kulik fullname: Gajkowska-Kulik, Justyna organization: Nicolaus Copernicus Municipal Specialist Hospital, Torun, Poland – sequence: 18 givenname: Grazyna surname: Gadomska fullname: Gadomska, Grazyna organization: Dr Biziel University Hospital, Bydgoszcz, Poland – sequence: 19 givenname: Marek surname: Kielbinski fullname: Kielbinski, Marek organization: Medical University of Wroclaw, Wroclaw, Poland – sequence: 20 givenname: Anna surname: Ejduk fullname: Ejduk, Anna organization: Institute of Hematology and Transfusion Medicine, Warsaw, Poland – sequence: 21 givenname: Dariusz surname: Kata fullname: Kata, Dariusz organization: Medical University of Silesia, Katowice, Poland – sequence: 22 givenname: Sebastian surname: Grosicki fullname: Grosicki, Sebastian organization: Municipal Specialist Hospital in Chorzow, Chorzow, Poland; and – sequence: 23 givenname: Agnieszka surname: Wierzbowska fullname: Wierzbowska, Agnieszka organization: Medical University of Lodz, Lodz, Poland – sequence: 24 givenname: Slawomira surname: Kyrcz-Krzemien fullname: Kyrcz-Krzemien, Slawomira organization: Medical University of Silesia, Katowice, Poland – sequence: 25 givenname: Krzysztof surname: Warzocha fullname: Warzocha, Krzysztof organization: Institute of Hematology and Transfusion Medicine, Warsaw, Poland – sequence: 26 givenname: Kazimierz surname: Kuliczkowski fullname: Kuliczkowski, Kazimierz organization: Medical University of Wroclaw, Wroclaw, Poland – sequence: 27 givenname: Aleksander surname: Skotnicki fullname: Skotnicki, Aleksander organization: Faculty of Medicine, Jagiellonian University, Cracow, Poland – sequence: 28 givenname: Jerzy surname: Holowiecki fullname: Holowiecki, Jerzy organization: Maria Sklodowska-Curie Institute of Oncology, Gliwice, Poland – sequence: 29 givenname: Wieslaw Wiktor surname: Jedrzejczak fullname: Jedrzejczak, Wieslaw Wiktor organization: Medical University of Warsaw, Warsaw, Poland – sequence: 30 givenname: Olga surname: Haus fullname: Haus, Olga organization: Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Bydgoszcz, Poland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26567156$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kMtKxDAUhoMoOl7eQCR7iZ6kTZpuBBmvMOJmXIc0SSXaSUrSDszb23HUpasDh_87l-8Y7YcYHELnFK4oley66WK0hAHlBCQRgtEC9tCMciYJAIN9NAMAQcq6okfoOOcPAFoWjB-iIya4qCgXM5TmnbbJNz44rK11Fg8RWz2GmMbGGx-I2Qw66e-AD3Y0g48B9yl2MbxnnMe09mvd4djih8WyIM_Lu0s80aup96nTJg6b3uHblwXu9eBdGPIpOmh1l93ZTz1Bbw_3y_kTWbw-Ps9vF8QwXgDhVV3rkpaC1QJqrampS-BWS8OrwrKidYJZLlshnKy0LJ20umK2hcbAFOXFCSp3c02KOSfXqj751XSSoqC2CtW3QrVVqECqncIJu9hh_disnP2Dfp1NgZtdwE3Hr71LKpvpMeOsT84Mykb__4YvYmiFWg |
| CitedBy_id | crossref_primary_10_1080_10428194_2019_1678151 crossref_primary_10_1007_s11523_017_0503_8 crossref_primary_10_3389_fonc_2022_1069246 crossref_primary_10_1002_ajh_27054 crossref_primary_10_1007_s00277_020_03923_9 crossref_primary_10_1002_ijc_34419 crossref_primary_10_1038_s41375_018_0135_8 crossref_primary_10_1016_S2352_3026_21_00270_2 crossref_primary_10_1080_16078454_2021_1962047 crossref_primary_10_3389_fonc_2024_1395992 crossref_primary_10_1177_1060028017749214 crossref_primary_10_1038_s41408_021_00495_3 crossref_primary_10_1080_10428194_2016_1235274 crossref_primary_10_1002_ajh_26451 crossref_primary_10_1007_s00277_019_03723_w crossref_primary_10_1111_bjh_18646 crossref_primary_10_1080_10428194_2019_1672060 crossref_primary_10_1634_theoncologist_2020_0818 crossref_primary_10_1007_s00277_017_3204_6 crossref_primary_10_1002_ajh_26557 crossref_primary_10_1007_s00277_018_3562_8 crossref_primary_10_1038_s41598_021_88120_y crossref_primary_10_1002_cam4_3681 crossref_primary_10_1016_j_clml_2021_05_016 crossref_primary_10_1016_j_leukres_2018_03_005 crossref_primary_10_1038_s41408_021_00425_3 crossref_primary_10_1007_s00277_024_05791_z crossref_primary_10_1007_s00277_016_2774_z crossref_primary_10_1002_cncr_33477 crossref_primary_10_3892_ol_2019_11051 crossref_primary_10_1016_j_annonc_2022_11_004 crossref_primary_10_18632_oncotarget_8938 |
| Cites_doi | 10.1038/leu.2009.113 10.1038/sj.leu.2402622 10.1080/1042819021000035608 10.1182/blood-2002-05-1440 10.1182/blood-2005-08-3167 10.1182/blood.V124.21.373.373 10.1158/1078-0432.CCR-14-0327 10.1158/1078-0432.CCR-13-1323 10.3109/10428194.2011.621562 10.1038/sj.leu.2403336 10.1111/j.1365-2141.2008.07461.x 10.1056/NEJMoa074306 10.1200/JCO.2011.37.1286 10.1182/blood-2003-01-0162 10.1182/blood.V98.6.1752 |
| ContentType | Journal Article |
| Copyright | 2016 American Society of Hematology |
| Copyright_xml | – notice: 2016 American Society of Hematology |
| DBID | 6I. AAFTH CGR CUY CVF ECM EIF NPM AAYXX CITATION |
| DOI | 10.1182/blood-2015-08-662130 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| EndPage | 362 |
| ExternalDocumentID | 10_1182_blood_2015_08_662130 26567156 S0006497120305425 |
| Genre | Letter Research Support, Non-U.S. Gov't |
| GroupedDBID | --- -~X .55 1CY 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6I. 6J9 AAEDW AAFTH AAXUO ABOCM ABVKL ACGFO ADBBV AENEX AFOSN AHPSJ ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD EX3 F5P FDB FRP GS5 GX1 IH2 K-O KQ8 L7B LSO MJL N9A OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV ZA5 0R~ 0SF AALRI ADVLN AFETI AITUG AKRWK AMRAJ CGR CUY CVF ECM EIF H13 NPM AAYXX CITATION |
| ID | FETCH-LOGICAL-c2530-5799a414629609aa1c9405da8c573d23fe62d58f66e87a84e8da72df0bc0c9453 |
| IEDL.DBID | ABVKL |
| ISSN | 0006-4971 |
| IngestDate | Fri Nov 22 01:03:44 EST 2024 Sat Sep 28 08:26:13 EDT 2024 Fri Feb 23 02:45:00 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | This article is made available under the Elsevier license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c2530-5799a414629609aa1c9405da8c573d23fe62d58f66e87a84e8da72df0bc0c9453 |
| ORCID | 0000-0002-5344-345X |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0006497120305425 |
| PMID | 26567156 |
| PageCount | 3 |
| ParticipantIDs | crossref_primary_10_1182_blood_2015_08_662130 pubmed_primary_26567156 elsevier_sciencedirect_doi_10_1182_blood_2015_08_662130 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-01-21 2016-Jan-21 |
| PublicationDateYYYYMMDD | 2016-01-21 |
| PublicationDate_xml | – month: 01 year: 2016 text: 2016-01-21 day: 21 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2016 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Thiede, Koch, Creutzig (bib7) 2006; 107 Schlenk, Döhner, Krauter, German-Austrian Acute Myeloid Leukemia Study Group (bib1) 2008; 358 Robak (bib3) 2003; 44 Holowiecki, Grosicki, Giebel (bib5) 2012; 30 Luskin, Lee, Fernandez (bib12) 2014 Baker, Zimmerman, Wang (bib2) 2013; 19 Larson, Campbell, Huo (bib13) 2012; 53 Kottaridis, Gale, Frew (bib8) 2001; 98 Sehgal, Gimotty, Zhao (bib11) 2015; 21 Mahlknecht, Dransfeld, Bulut (bib15) 2009; 23 Bhatla, Gerbing, Alonzo (bib14) 2009; 144 Holowiecki, Grosicki, Robak, Polish Adult Leukemia Group (PALG) (bib4) 2004; 18 Boissel, Cayuela, Preudhomme (bib9) 2002; 16 Fröhling, Schlenk, Breitruck (bib10) 2002; 100 Libura, Asnafi, Tu (bib6) 2003; 102 Holowiecki (2019111905590643000_B5) 2012; 30 Luskin (2019111905590643000_B12) 2014 Bhatla (2019111905590643000_B14) 2009; 144 Schlenk (2019111905590643000_B1) 2008; 358 Kottaridis (2019111905590643000_B8) 2001; 98 Boissel (2019111905590643000_B9) 2002; 16 Larson (2019111905590643000_B13) 2012; 53 Thiede (2019111905590643000_B7) 2006; 107 Holowiecki (2019111905590643000_B4) 2004; 18 Fröhling (2019111905590643000_B10) 2002; 100 Baker (2019111905590643000_B2) 2013; 19 Robak (2019111905590643000_B3) 2003; 44 Libura (2019111905590643000_B6) 2003; 102 Sehgal (2019111905590643000_B11) 2015; 21 Mahlknecht (2019111905590643000_B15) 2009; 23 |
| References_xml | – volume: 107 start-page: 4011 year: 2006 end-page: 4020 ident: bib7 article-title: Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML) publication-title: Blood contributor: fullname: Creutzig – volume: 16 start-page: 1699 year: 2002 end-page: 1704 ident: bib9 article-title: Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy publication-title: Leukemia contributor: fullname: Preudhomme – volume: 144 start-page: 388 year: 2009 end-page: 394 ident: bib14 article-title: Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia publication-title: Br J Haematol contributor: fullname: Alonzo – volume: 358 start-page: 1909 year: 2008 end-page: 1918 ident: bib1 article-title: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia publication-title: N Engl J Med contributor: fullname: German-Austrian Acute Myeloid Leukemia Study Group – volume: 19 start-page: 5758 year: 2013 end-page: 5768 ident: bib2 article-title: Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia publication-title: Clin Cancer Res contributor: fullname: Wang – volume: 102 start-page: 2198 year: 2003 end-page: 2204 ident: bib6 article-title: FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress publication-title: Blood contributor: fullname: Tu – volume: 100 start-page: 4372 year: 2002 end-page: 4380 ident: bib10 article-title: AML Study Group Ulm. Acute myeloid leukemia Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm publication-title: Blood contributor: fullname: Breitruck – volume: 53 start-page: 445 year: 2012 end-page: 450 ident: bib13 article-title: High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML) publication-title: Leuk Lymphoma contributor: fullname: Huo – volume: 23 start-page: 1929 year: 2009 end-page: 1932 ident: bib15 article-title: SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival publication-title: Leukemia contributor: fullname: Bulut – volume: 44 start-page: 391 year: 2003 end-page: 409 ident: bib3 article-title: Purine nucleoside analogues in the treatment of myleoid leukemias publication-title: Leuk Lymphoma contributor: fullname: Robak – volume: 18 start-page: 989 year: 2004 end-page: 997 ident: bib4 article-title: Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study publication-title: Leukemia contributor: fullname: Polish Adult Leukemia Group (PALG) – volume: 98 start-page: 1752 year: 2001 end-page: 1759 ident: bib8 article-title: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials publication-title: Blood contributor: fullname: Frew – volume: 30 start-page: 2441 year: 2012 end-page: 2448 ident: bib5 article-title: Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study publication-title: J Clin Oncol contributor: fullname: Giebel – volume: 21 start-page: 1614 year: 2015 end-page: 1620 ident: bib11 article-title: DNMT3A mutational status affects the results of dose-escalated induction therapy in acute myelogenous leukemia publication-title: Clin Cancer Res contributor: fullname: Zhao – year: 2014 ident: bib12 article-title: High dose daunorubicin improves survival in AML up to age 60, across all cytogenetic risk groups including patients with unfavorable cytogenetic risk, and FLT3-ITD mutant AML: updated analyses from Eastern Cooperative Oncology Trial E1900 [abstract] publication-title: Blood contributor: fullname: Fernandez – volume: 23 start-page: 1929 issue: 10 year: 2009 ident: 2019111905590643000_B15 article-title: SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. publication-title: Leukemia doi: 10.1038/leu.2009.113 contributor: fullname: Mahlknecht – volume: 16 start-page: 1699 issue: 9 year: 2002 ident: 2019111905590643000_B9 article-title: Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. publication-title: Leukemia doi: 10.1038/sj.leu.2402622 contributor: fullname: Boissel – volume: 44 start-page: 391 issue: 3 year: 2003 ident: 2019111905590643000_B3 article-title: Purine nucleoside analogues in the treatment of myleoid leukemias. publication-title: Leuk Lymphoma doi: 10.1080/1042819021000035608 contributor: fullname: Robak – volume: 100 start-page: 4372 issue: 13 year: 2002 ident: 2019111905590643000_B10 article-title: Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. publication-title: Blood doi: 10.1182/blood-2002-05-1440 contributor: fullname: Fröhling – volume: 107 start-page: 4011 issue: 10 year: 2006 ident: 2019111905590643000_B7 article-title: Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). publication-title: Blood doi: 10.1182/blood-2005-08-3167 contributor: fullname: Thiede – year: 2014 ident: 2019111905590643000_B12 article-title: High dose daunorubicin improves survival in AML up to age 60, across all cytogenetic risk groups including patients with unfavorable cytogenetic risk, and FLT3-ITD mutant AML: updated analyses from Eastern Cooperative Oncology Trial E1900 [abstract]. publication-title: Blood doi: 10.1182/blood.V124.21.373.373 contributor: fullname: Luskin – volume: 21 start-page: 1614 issue: 7 year: 2015 ident: 2019111905590643000_B11 article-title: DNMT3A mutational status affects the results of dose-escalated induction therapy in acute myelogenous leukemia. publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-0327 contributor: fullname: Sehgal – volume: 19 start-page: 5758 issue: 20 year: 2013 ident: 2019111905590643000_B2 article-title: Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-1323 contributor: fullname: Baker – volume: 53 start-page: 445 issue: 3 year: 2012 ident: 2019111905590643000_B13 article-title: High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). publication-title: Leuk Lymphoma doi: 10.3109/10428194.2011.621562 contributor: fullname: Larson – volume: 18 start-page: 989 issue: 5 year: 2004 ident: 2019111905590643000_B4 article-title: Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. publication-title: Leukemia doi: 10.1038/sj.leu.2403336 contributor: fullname: Holowiecki – volume: 144 start-page: 388 issue: 3 year: 2009 ident: 2019111905590643000_B14 article-title: Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2008.07461.x contributor: fullname: Bhatla – volume: 358 start-page: 1909 issue: 18 year: 2008 ident: 2019111905590643000_B1 article-title: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. publication-title: N Engl J Med doi: 10.1056/NEJMoa074306 contributor: fullname: Schlenk – volume: 30 start-page: 2441 issue: 20 year: 2012 ident: 2019111905590643000_B5 article-title: Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. publication-title: J Clin Oncol doi: 10.1200/JCO.2011.37.1286 contributor: fullname: Holowiecki – volume: 102 start-page: 2198 issue: 6 year: 2003 ident: 2019111905590643000_B6 article-title: FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. publication-title: Blood doi: 10.1182/blood-2003-01-0162 contributor: fullname: Libura – volume: 98 start-page: 1752 issue: 6 year: 2001 ident: 2019111905590643000_B8 article-title: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. publication-title: Blood doi: 10.1182/blood.V98.6.1752 contributor: fullname: Kottaridis |
| SSID | ssj0014325 |
| Score | 2.2232528 |
| SourceID | crossref pubmed elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 360 |
| SubjectTerms | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cladribine - administration & dosage Cytarabine - administration & dosage Daunorubicin - administration & dosage fms-Like Tyrosine Kinase 3 - genetics Gene Duplication Humans Karyotype Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - mortality Treatment Outcome |
| Title | Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients |
| URI | https://dx.doi.org/10.1182/blood-2015-08-662130 https://www.ncbi.nlm.nih.gov/pubmed/26567156 |
| Volume | 127 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwEB7tdsXjgqDLY3msfEBckNXEsR3n2C1UC9siIXXR3iLHD1RRklXaHvrvGSfOCi4gcYkiy04sz-ibb8bjMcDbwlgT6ohR5ZWg3GtPkcdZfGibZEaaogrxjuUXeXnNP9-ImyOYDWdhQlplxP4e0zu0ji2TuJqT2_U6nPFFc1rkKQs6i6p3DCcsR_o8gpPpxberxd1mAs9Yf5EBOs9hQDxBh8x60meHoxEUIU4oJUtDOvRfLdRv5mf-GB5F3kim_dSewJGrx3A6rdFn_nkg70iXydmFyMdw72J4ezAb7nMbw_1l3EY_hXa20bZdo1PsSEAeS3YNsXpfN-2-Cn2oOex0q7sO6LT3FWYJgu2mqb9vyXaPAIMqShpP5otVRj-tPrwndaC_G_JDt4cmRHbJdLkgsW7r9ilczz-uZpc0Xr5ADRNZQkVeFJojjrJQk07r1BTI7axWRuSZZZl3klmhvJRO5Vpxp6zOmfVJZRLsKrJnMKqb2r0AwpnPrTGVs1rwykqtM2l9WnHleOJNcgZ0WPDytq-xUXa-iWJlJ6AyCKhMVNkL6AzyQSrlH7pSohn4x8jnvRDv_sOQz-bow77872--gofY0IVlWPoaRrt2794gUdlV51ERz-H46qv6BT4t5ek |
| link.rule.ids | 315,782,786,27576,27931,27932,45670 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwEB4tXcFyQdDlsTx9QFyQ1cSJHefYLVRdNt1TF-3NcvxYVZRklbaH_nvGeazgAhKXKErsOPKMvvlmPB4DfMyNNaGOGJVecpp67SnyOIsXbaPECJOXId6xvBKL6_TbDb85gtmwFyakVfbY32F6i9b9k0k_m5O79Trs8UVzmmcxCzqLqvcAjpENZNEIjqfn3y-L-8WENGHdQQboPIcO_Q46ZNaTLjscjSAPcUIhWBzSof9qoX4zP_On8KTnjWTa_dozOHLVGE6nFfrMPw_kE2kzOdsQ-Rgeng93J7PhPLcxPFr2y-in0Mw22jZrdIodCchjya4mVu-rutmXoQ01h51udNsAnfauwixBsN3U1e2WbPcIMKiipPZkXqwSerH68plUgf5uyA_dHOoQ2SXTZUH6uq3b53A9_7qaLWh_-AI1jCcR5Vme6xRxlIWadFrHJkduZ7U0PEssS7wTzHLphXAy0zJ10uqMWR-VJsKmPHkBo6qu3CsgKfOZNaZ0VvO0tELrRFgfl6l0aeRNdAZ0mHB119XYUK1vIplqBaSCgFQkVSegM8gGqag_dEWhGfhHz5edEO_HYchnM_RhX__3Nz_AyWK1LFRxcXX5Bh7jyzZEw-K3MNo1e_cOScuufN8r5S-sZefZ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cladribine+added+to+daunorubicin-cytarabine+induction+prolongs+survival+of+FLT3-ITD%2B+normal+karyotype+AML+patients&rft.jtitle=Blood&rft.au=Libura%2C+Marta&rft.au=Giebel%2C+Sebastian&rft.au=Piatkowska-Jakubas%2C+Beata&rft.au=Pawelczyk%2C+Marta&rft.date=2016-01-21&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=127&rft.issue=3&rft.spage=360&rft.epage=362&rft_id=info:doi/10.1182%2Fblood-2015-08-662130&rft.externalDBID=n%2Fa&rft.externalDocID=10_1182_blood_2015_08_662130 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon |